# Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids

> **NCT03442972** · PHASE2,PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 21 (actual)

## Conditions studied

- Hyperlipidemias

## Interventions

- **DRUG:** Teduglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03442972
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03442972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03442972, "Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03442972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*